Biotech Archives - Page 122 of 795

4 minute read

Spruce Biosciences Completes Enrollment In CAHmelia-204 Study For Adult Classic Congenital Adrenal Hyperplasia; 100 Patients Enrolled, Exceeding Target Enrollment Of 90 Patients

January 22, 9:03 AM

100 Patients Enrolled, Exceeding Target Enrollment of 90 PatientsTopline Results for CAHmelia-204 Anticipated in the Third Quarter of 2024Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company

SPRB

3 minute read

Seelos Therapeutics Announces Receipt Of Minutes From Its End Of Phase II Meeting With The U.S. FDA Highlighting Modifications To The Primary And Secondary Endpoints Of Its Phase II Study Of SLS-002

By Benzinga Newsdesk

January 22, 9:01 AM

Company plans to continue its previously announced potential partnership discussions and expects to proceed to Phase III with SLS-002 in Adults with Major Depressive Disorder (MDD) at Imminent Risk of SuicideNEW YORK,

SEEL

2 minute read

Bristol Myers’ Lead Cancer Immunotherapy Shows Progression Free Survival Versus Chemo In Certain Type Of Colorectal Cancer

By Vandana Singh

January 22, 8:07 AM

Bristol Myers' Opdivo + Yervoy combo shows 79% reduced risk in MSI-H/dMMR metastatic colorectal cancer.

BMY

1 minute read

Federal Court Allows Vanda Pharmaceuticals’ Lawsuit To Proceed Against The U.S. Food And Drug Administration

By Benzinga Newsdesk

January 19, 4:57 PM

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the United States Court of Federal Claims in Washington, D.C. denied in part the government's motion to dismiss Vanda's claim against the United

VNDA

2 minute read

Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes

By Vandana Singh

January 19, 3:55 PM

Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workforce reduced by 35%. Financially secure with $175M cash. Strategic focus on key developments in 2024.

BMY

2 minute read

Amgen’s Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning

By Vandana Singh

January 19, 2:29 PM

FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups.

AMGN

2 minute read

Healthcare Giant Eli Lilly Under FDA Lens Again For Manufacturing Lapses

By Vandana Singh

January 19, 2:21 PM

Eli Lilly faces FDA scrutiny with eight deficiencies at its Branchburg plant, raising concerns on Emgality's manufacturing.

LLY

2 minute read

AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study

By Vandana Singh

January 19, 1:41 PM

Explore results from AstraZeneca's EMERALD-1 Phase 3 trial on Imfinzi for unresectable hepatocellular carcinoma. Statistically significant improvement in progression-free survival with Imfinzi plus TACE and bevacizumab. Presented at ASCO Gastrointestinal Cancers Symposium.

AZN

2 minute read

Vaxart Receives $9.27M BARDA Project NextGen Award To Prepare For Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

By Benzinga Newsdesk

January 19, 9:30 AM

- 10,000-subject Phase 2b study would evaluate Vaxart's next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator - - Project NextGen is a $5 billion initiative by the U.S.

VXRT

2 minute read

Weightloss Drugs Ozempic And Wegovy’s Success Sets Novo Nordisk’s Owner To Utilize Dividend Windfall For Strategic Investments

By Vandana Singh

January 19, 9:30 AM

Explore Novo Holdings' 2024 plans for acquisitions and investments in Asia, led by CEO Kasim Kutay. Discover strategic initiatives, global studies on NVO drugs, and insights into challenges and opportunities.

NVO